INNOCARE PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.17 HKD | +3.19% |
|
+11.66% | -24.96% |
ETFs positioned on InnoCare Pharma Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.14% | 4 M€ | -27.92% | ||
| 0.13% | 2 M€ | -14.14% | ||
| 0.01% | 0 M€ | +3.77% | - | |
| 0.00% | 0 M€ | +4.12% | - | |
| 0.00% | 0 M€ | +3.39% | - |
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.779
CNY
Average target price
8.944
CNY
Spread / Average Target
+87.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.96% | 1.28B | |
| +2.97% | 108B | |
| +10.32% | 105B | |
| +1.57% | 23.46B | |
| -12.55% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.54% | 17.19B | |
| +6.14% | 13.99B | |
| +37.14% | 12.53B |
- Stock Market
- Equities
- 9969 Stock
- Funds and ETFs InnoCare Pharma Limited